Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma
Authors:
- Adel ShahnamASAdel Shahnam
- Kristen DiConzaKDKristen DiConza
- Rhoena Desir-CamilleRDRhoena Desir-Camille
- Justin JeeJJJustin Jee
- Daniel ReinhornDRDaniel Reinhorn
- Olayode BabatundeOBOlayode Babatunde
- Ciara M. KellyCKCiara M. Kelly
- Carla SaoudCSCarla Saoud
- Samuel SingerSSSamuel Singer
- Aimee M. CragoACAimee M. Crago
- Ping ChiPCPing Chi
- Sujana MovvaSMSujana Movva
Open Access
Abstract
Background: The incidence and risk factors for central nervous system (CNS) metastases in soft tissue sarcoma (STS) are poorly defined. We evaluated the frequency of CNS metastases in STS and associated clinicopathologic and genomic factors. Methods: This retrospective study used the Memorial Sloan Kettering Cancer Center institutional cBioPortal database. Patients with invasive STS, including gastrointestinal stromal tumor, were included. CNS metastases were identified using natural language processing-derived radiology annotations and confirmed by manual chart review. Cumulative incidence was estimated with death as a competing event. Clinicopathologic and genomic associations were evaluated using Firth logistic regression with correction for multiplicity; post-CNS metastasis survival was estimated using Kaplan–Meier analysis. Results: A total of 5379 patients were included. CNS metastases were identified in 161 patients (3.0%), with a 10-year cumulative incidence of 4.5% after accounting for death as a competing event. Median overall survival after CNS metastasis was 4.76 months (95% CI, 3.9–7.5). In one-versus-rest analyses, increased odds of CNS metastasis were observed for alveolar soft part sarcoma (OR 16.61, 95% CI 7.21–35.81; q < 0.001), rhabdomyosarcoma (OR 2.44, 95% CI 1.42–3.97; q = 0.007), non-uterine leiomyosarcoma (OR 2.24, 95% CI 1.45–3.34; q = 0.003), extremity primaries (OR 2.20, 95% CI 1.58–3.05; q < 0.001), head and neck primaries (OR 2.11, 95% CI 1.26–3.35; q = 0.017), and PDGFRB alterations (OR 4.90, 95% CI 2.29–9.41; q = 0.016). KIT alterations were associated with lower odds (OR 0.10, 95% CI 0.02–0.29; q < 0.001). Conclusions: CNS metastases in STS were uncommon but associated with poor survival, with risk varying by histology and primary site.Keywords
This publication has 27 references indexed in Scilit:
- Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and TreatmentJAMA Oncology, 2025
- Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma GroupCritical Reviews in Oncology/Hematology, 2025
- Analysis of clinicopathological characteristics in rhabdomyosarcoma and identification of risk factors for metastasis to the lung, bone, liver, and brain: a population-based cohort studyDiscover Oncology, 2025
- Brain metastases of sarcoma: a rare phenomenon in rare tumoursJournal of Cancer Research and Clinical Oncology, 2023
- Oncogenic Signaling Pathways in The Cancer Genome AtlasCell, 2018
- Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysisThe Lancet Oncology, 2016
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002
- Soft tissue sarcoma brain metastasesCancer, 2002
- Alveolar soft part sarcomaCancer, 2001